PUBLICATION

CPhI

AUTHORS

JP Stevenson, Alex Heeley

Turkey Pharma 2014 CPhI Pharmaceuticals Insights

May 03, 2014

Estimated to reach a value of $36 billion by 2023, Turkey’s pharmaceuticals manufacturing industry shows strong growth potential. Government support, high technological standards, and logistical advantages make Turkey an excellent place to manufacture and export pharmaceuticals. If the public and private sectors can collaborate to improve practices and profit margins, the country will become a global pharmaceuticals powerhouse.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

USA Mining 2025-26 - Pre-release

USA Mining 2025-26 pre-release is a snapshot capturing insights from over 70 executives and decision-makers across the value chain and from coast to coast, sharing not only how the industry is changing, but also where it is heading next.

MORE PREVIOUSLY PUBLISHED

MACIG

"DFC has the ability to invest equity and to support earlier stage opportunity through project development grants, and an expanded mandate enables greater investment that meets US interests."

SUBSCRIBE TO OUR NEWSLETTER